Allosteric Potentiators of Metabotropic Glutamate Receptor Subtype 5 Have Differential Effects on Different Signaling Pathways in Cortical Astrocytes
- 1 December 2005
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 315 (3) , 1212-1219
- https://doi.org/10.1124/jpet.105.090308
Abstract
The metabotropic glutamate receptor subtype 5 (mGluR5) activates calcium mobilization and extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation in cortical astrocytes. These are independent signaling systems, and they can be differentially regulated. We recently discovered two novel selective allosteric potentiators of mGluR5, 3,3′-difluorobenzaldazine (DFB) and N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl) methyl]phenyl}-2-hydroxybenzamide (CPPHA). In studies of mGluR5 activation of calcium transients in recombinant systems, both DFB and CPPHA are without effect on baseline calcium levels, but they induce parallel leftward shifts in the concentration-response curve to agonists. However, it is conceivable that these compounds will have differential effects on different signaling pathways in native systems. Here, we examined the effects of CPPHA and DFB on mGluR5-induced calcium transients and ERK1/2 phosphorylation in cultured rat cortical astrocytes. Both potentiators induced parallel leftward shifts of the concentration-response curves of DHPG- and glutamate-induced calcium transients in astrocytes. These effects are identical to their effects on mGluR5 expressed in human embryonic kidney 293 or Chinese hamster ovary cells. DFB induced a similar shift of concentration-response curve of DHPG-induced ERK1/2 phosphorylation. Interestingly, CPPHA induced an increase in basal mGluR5-mediated ERK1/2 phosphorylation and potentiated the effect of low concentrations of agonists. In contrast, CPPHA significantly decreased ERK1/2 phosphorylation induced by high concentrations of agonists. Thus, CPPHA has qualitatively different effects on mGluR5-mediated calcium responses and ERK1/2 phosphorylation. Together, these data provide evidence that different allosteric potentiators can differentially modulate coupling of a single receptor to different signaling pathways.This publication has 41 references indexed in Scilit:
- 3-(2-Ethoxy-4-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy}phenyl)propanoic acid: a brain penetrant allosteric potentiator at the metabotropic glutamate receptor 2 (mGluR2)Bioorganic & Medicinal Chemistry Letters, 2005
- The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in ratsPsychopharmacology, 2004
- Functional coupling of the human dopamine D2receptor with Gαi1, Gαi2, Gαi3and GαoG proteins: evidence for agonist regulation of G protein selectivityBritish Journal of Pharmacology, 2003
- Metabotropic Glutamate Receptors: Potential Drug Targets for the Treatment of SchizophreniaCurrent Drug Targets-CNS & Neurological Disorders, 2002
- Multiple Active States and Oligomerization of CCR5 Revealed by Functional Properties of Monoclonal AntibodiesMolecular Biology of the Cell, 2002
- Peripheral group I metabotropic glutamate receptors modulate nociception in miceNature Neuroscience, 2001
- Activation of N‐Methyl‐D‐Aspartate Receptors Reverses Desensitization of Metabotropic Glutamate Receptor, mGluR5, in Native and Recombinant SystemsAnnals of the New York Academy of Sciences, 1999
- Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systemsNature Neuroscience, 1999
- Effector Pathway-Dependent Relative Efficacy at Serotonin Type 2A and 2C Receptors: Evidence for Agonist-Directed Trafficking of Receptor StimulusMolecular Pharmacology, 1998
- PHARMACOLOGY AND FUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTORSAnnual Review of Pharmacology and Toxicology, 1997